PhD in Biomarker Discovery for ALS: The Leuven Center for ALS Research (LEUCALS) is inviting applications for a PhD candidate to join an interdisciplinary research project focusing on the identification and validation of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis (ALS).
Designation
PhD Scholar
Table
| Element | Details |
|---|---|
| Research Area | Biomarker Discovery for ALS |
| Location | KU Leuven, Leuven, Belgium |
| Eligibility/Qualification | Master’s degree in biomedical sciences, neuroscience, molecular biology, biochemistry, bioinformatics, or a related discipline |
| Last Date to Apply | January 30, 2026 |
Research Area
- Identification and validation of ALS-associated biomarkers from cerebrospinal fluid (CSF) using advanced immunoassay platforms.
Eligibility/Qualification
- Master’s degree in biomedical sciences, neuroscience, molecular biology, biochemistry, bioinformatics, or related disciplines.
- Strong interest in neurodegenerative diseases, particularly ALS.
- Hands-on experience or motivation to learn immunoassay techniques (ELISA, NULISA, etc.).
- Familiarity with RNA-seq and multi-omics data analysis; prior bioinformatics experience is advantageous.
- Strong analytical thinking, organizational skills, and scientific curiosity.
- Excellent written and verbal communication skills in English.
Description
This PhD position offers an opportunity to work in a collaborative environment at KU Leuven, combining experimental neuroscience, clinical research, and computational biology. The successful candidate will validate candidate biomarkers in human CSF or plasma/serum, engage in data analysis and statistical evaluation, and contribute to the development of diagnostic/prognostic biomarker panels.
How to Apply
Interested candidates should submit:
- A motivation letter highlighting research interests and suitability for the project.
- A detailed CV.
- Contact information for at least two academic referees.
Applications can be submitted via the online application tool at KU Leuven.
Last Date to Apply
January 30, 2026
